Xeltis

Invest-NL, as a new shareholder, participates in the series D2 funding round of €32 million in Xeltis, a MedTech company based in Eindhoven. Xeltis focuses on developing vascular implants in which the patient's own living cells integrate with the implant, thereby restoring natural cardiovascular function. The funding round is supported by a combination of current and new investors, including Grand Pharma, DaVita Venture Group, EQT Life Sciences, and Invest-NL, along with other international investors.

The newly raised funds allow Xeltis to make significant progress in its key clinical programmes. Ultimately, these advances aim to enable patients worldwide to access the most advanced regenerative cardiovascular therapies globally.